Long-term safety of tezepelumab in Japanese Subjects with Inadequately Controlled Severe Asthma - NOZOMI

Study identifier:D5180C00019

ClinicalTrials.gov identifier:NCT04048343

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tezepelumab in Japanese Adults and Adolescents with Inadequately Controlled Severe Asthma (NOZOMI)

Medical condition

Severe Asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

Biological: Experimental: Tezepelumab

Sex

All

Actual Enrollment

65

Study type

Interventional

Age

12 Years - 80 Years

Date

Study Start Date: 10 Jun 2019
Primary Completion Date: 18 Mar 2021
Study Completion Date: 18 Mar 2021

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Amgen

Inclusion and exclusion criteria